BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 18790799)

  • 1. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.
    Passamonti F; Rumi E; Arcaini L; Boveri E; Elena C; Pietra D; Boggi S; Astori C; Bernasconi P; Varettoni M; Brusamolino E; Pascutto C; Lazzarino M
    Haematologica; 2008 Nov; 93(11):1645-51. PubMed ID: 18790799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.
    Alvarez-Larrán A; Cervantes F; Bellosillo B; Giralt M; Juliá A; Hernández-Boluda JC; Bosch A; Hernández-Nieto L; Clapés V; Burgaleta C; Salvador C; Arellano-Rodrigo E; Colomer D; Besses C
    Leukemia; 2007 Jun; 21(6):1218-23. PubMed ID: 17519959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.
    Gangat N; Tefferi A; Thanarajasingam G; Patnaik M; Schwager S; Ketterling R; Wolanskyj AP
    Eur J Haematol; 2009 Jul; 83(1):17-21. PubMed ID: 19236446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
    Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
    J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
    Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
    Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.
    Passamonti F; Malabarba L; Orlandi E; Baratè C; Canevari A; Brusamolino E; Bonfichi M; Arcaini L; Caberlon S; Pascutto C; Lazzarino M
    Haematologica; 2003 Jan; 88(1):13-8. PubMed ID: 12551821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia.
    Chim CS; Kwong YL; Lie AK; Ma SK; Chan CC; Wong LG; Kho BC; Lee HK; Sim JP; Chan CH; Chan JC; Yeung YM; Law M; Liang R
    Arch Intern Med; 2005 Dec 12-26; 165(22):2651-8. PubMed ID: 16344424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of myeloproliferative neoplasms other than chronic leukemia].
    Ohyashiki JH
    Nihon Rinsho; 2009 Oct; 67(10):1964-8. PubMed ID: 19860198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia.
    Hsiao HH; Ito Y; Sashida G; Ohyashiki JH; Ohyashiki K
    Leuk Res; 2005 Nov; 29(11):1247-52. PubMed ID: 16164981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
    Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The risk factors for thrombosis, myelofibrosis and leukemia transformation in patients with polycythemia vera].
    Bai J; Xue YP; Ye L; Yao JF; Zhou CL; Qian LS; Yang RC; Li HY; Zhang HY; Shao ZH
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):685-8. PubMed ID: 18399175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia.
    Radaelli F; Colombi M; Calori R; Zilioli VR; Bramanti S; Iurlo A; Zanella A
    Hematol Oncol; 2007 Sep; 25(3):115-20. PubMed ID: 17464935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.
    Palandri F; Catani L; Testoni N; Ottaviani E; Polverelli N; Fiacchini M; De Vivo A; Salmi F; Lucchesi A; Baccarani M; Vianelli N
    Am J Hematol; 2009 Apr; 84(4):215-20. PubMed ID: 19208420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.
    Passamonti F; Rumi E; Pungolino E; Malabarba L; Bertazzoni P; Valentini M; Orlandi E; Arcaini L; Brusamolino E; Pascutto C; Cazzola M; Morra E; Lazzarino M
    Am J Med; 2004 Nov; 117(10):755-61. PubMed ID: 15541325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
    Ohyashiki K; Kodama A; Ohyashiki JH
    Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex and age as prognostic factors in essential thrombocythemia.
    Randi ML; Fabris F; Rossi C; Tison T; Barbone E; Girolami A
    Haematologica; 1992; 77(5):402-4. PubMed ID: 1483589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.